"Early Feasibility Study of HyperQureTM RDN System, Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension"

NARecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 5, 2024

Primary Completion Date

August 18, 2025

Study Completion Date

May 18, 2028

Conditions
Resistant Hypertension
Interventions
DEVICE

HyperQureTM Renal Denervation (RDN) System:

"The HyperQure RDN System consists of a Generator that generates RF energy and a Laparoscopic Instrument that delivers the RF energy generated by the generator to the treatment area. Through a extravascular(laparoscopic) approach, the renal artery is accessed through the retroperitoneum, which is the closest path to the renal artery. After wrapping 360 degrees of renal artery, RDN is performed as per the preset parameters of 50 degrees and 70 seconds.~The target blood vessels will be planned by CTA before the procedure, and the proximal and distal areas of the right and left main renal artery are treated once at a distance of at least 3 mm respectively, and RDN will be also performed on the branch or accessory vessels confirmed to be suitable for the procedure by CTA."

Trial Locations (5)

30303

NOT_YET_RECRUITING

Emory University Medical Center, Atlanta

55905

NOT_YET_RECRUITING

Mayo Clinic, Rochester

85719

NOT_YET_RECRUITING

University of Arizona Department of Urology, Tucson

92868

RECRUITING

University of California Irvine, Orange

94305

NOT_YET_RECRUITING

Stanford Health Care, Stanford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

DeepQure Inc.

INDUSTRY